ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

Rhea-AI Summary

ImmunoGen, Inc. (NASDAQ: IMGN) announced the presentation of final overall survival data from the SORAYA trial for mirvetuximab soravtansine, targeting platinum-resistant ovarian cancer with high folate receptor alpha expression. This presentation will occur on March 25, 2023, at the Society of Gynecologic Oncology Annual Meeting in Tampa, Florida, led by Dr. Robert Coleman. The study assesses the impact of therapy sequencing on anti-tumor activity.

ImmunoGen focuses on developing innovative antibody-drug conjugates (ADCs) to enhance cancer treatment outcomes, aiming for a commitment to TARGET A BETTER NOW™.

Positive

• Presentation of pivotal SORAYA trial results could bolster investor confidence.
• Potential for improved treatment outcomes for patients with platinum-resistant ovarian cancer.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.

Oral Presentation Details
Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study
Session: Scientific Plenary I: Progress: Therapeutics Innovations
Session Date: Saturday, March 25, 2023
Session Time: 9:00 am to 10:30 am ET

Additional information can be found at www.sgo.org.

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230325005002/en/

INVESTOR RELATIONS

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com



MEDIA

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com



OR



FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

FAQ

What is the focus of ImmunoGen's presentation at the SGO 2023 Annual Meeting?

ImmunoGen will present final overall survival data from the SORAYA trial of mirvetuximab soravtansine for platinum-resistant ovarian cancer.

When will the SORAYA trial results be presented?

The results will be presented on March 25, 2023, during a plenary session at the SGO Annual Meeting.

Who will present the SORAYA trial findings?

Dr. Robert Coleman will present the findings from the SORAYA trial.

What is the significance of the SORAYA trial for ImmunoGen?

The SORAYA trial results may enhance ImmunoGen's reputation and credibility in developing targeted cancer therapies.